Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 801–900 of 1,000
Michiels, J. J., Moossdorff, W., Strijkers, R., Lao, M. U., Smeets, H., Han, M., Schroyens, W., & Gadisseur, A. (2020) · Acta Scientific Medical Sciences · doi:10.31080/asms.2020.04.0568 · Cited by 1
Terapia Anticoagulante para Tratamento da Trombose Venosa Profunda – O Que Há de Novo?
Sanches, S. M. V. (2020) · Revista Científica Hospital Santa Izabel · doi:10.35753/rchsi.v3i1.37 · Cited by 3
Long term use of anticoagulant therapy for patients with pulmonary embolism
Becattini, C., & Cimini, L. A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1770589 · Cited by 1
Günaydın, S., Budak, A. B., Günertem, E., Tümer, N. B., Kunt, A. T., & Özışık, K. (2020) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.796973 · Cited by 1
“Conversely, DOAC does not require regular INR testing and dose adjustments, while still remaining effective and safe in the treatment of VTE, with comparable rates of clinically significant bleeding and mortality [6].”
BackgroundВарданович, З. Н., Pankov, A. S., Shelesko, A. A., Davtyan, A. G., Molokhoev, E. B., Barinov, V., & Schastlivtsev, I. (2021) · Journal of Venous Disorders · doi:10.17116/flebo20211501158 · Cited by 1
The “Obesity Paradox” and the Use of NOAC
Bottino, R., Carbone, A., Liccardo, B., Golino, P., Nigro, G., & Russo, V. (2021) · Springer eBooks · doi:10.1007/978-3-030-74462-5_9 · Cited by 1
Venous Thromboembolism for the Practicing Cardiologist
Pribish, A. M., Secemsky, E. A., & Schmaier, A. A. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.06.008 · Cited by 1
Sánchez, F. S. L., Hernández, P. V., Castillo, J. Z., & Calvo, R. S. (2021) · Angiología · doi:10.20960/angiologia.00313 · Cited by 1
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-54630-7_18 · Cited by 1
Romanova, M. V., & Владимирович, П. Д. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4944 · Cited by 1
Antiphospholipid syndrome: the burden of inadequate anticoagulation management
Nassarmadji, K., Brigante, A. J., Larroche, C., Cacoub, P., Costedoat-Chalumeau, N., Guern, V. L., & Guillevin, L. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/gobuor · Cited by 1
“DOACs are as effective as VKA at reducing the risk of recurrent venous thromboembolism with a lower risk of major bleeding (5).”
BackgroundHemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
Liu, Z., Mu, G., Xie, Q., Zhang, H., Jiang, J., Xiang, Q., & Cui, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.894888 · Cited by 1
“Patients meeting the following criteria were included: (1) patients with NVAF using dabigatran for prevention of ischemic stroke and systemic embolism; (2) Age older than 18; (3) Baseline data were available.”
MethodKanjee, Z., Freed, J. A., Carroll, B., & Reynolds, E. E. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0989 · Cited by 1
Wille, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-66303-5_9 · Cited by 3
Александровна, Ш. Е., Penskaya, T. Y., Gruzdeva, O. V., Berns, S. A., Каретникова, В. Н., & Барбараш, О. Л. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3869 · Cited by 1
Flapless Dental Implant Surgery in Bleeding Disorders
Benetello, F., Zanon, E., Sbricoli, L., & Bacci, C. (2024) · International Journal of Translational Medicine · doi:10.3390/ijtm4020022 · Cited by 1
“To overcome these limitations, direct thrombin inhibitors and activated factor X inhibitors have recently been proposed as substitutes [7].”
BackgroundDuration of anticoagulation of venous thromboembolism
Couturaud, F., Meneveau, N. F., Sevestre, M., Morange, P., & Jiménez, D. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104245 · Cited by 1
del Pozo, M. M., Asenjo, M. M., Franco‐Moreno, A., de Antonio, E. U., & Valle, F. G. (2024) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2024.10.004 · Cited by 1
Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran
Strijbis, V. J. F., Cheung, K. L., Veizaj, D., Rutten, T. A., Bruin, B., Reitsma, P. H., Verhoef, D., & Bos, M. H. A. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2537-6037 · Cited by 1
Pan, J., Hao, Z., Sun, X., Gao, H., & Gao, B. (2020) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v19i9.29 · Cited by 1
Kakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.12.007 · Cited by 1
Lin, T., Pan, L.-F., & Jong, G. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219733 · Cited by 1
Duration of anticoagulation for unprovoked venous thromboembolism
Kimpton, M., & Wang, T. (2025) · BMJ · doi:10.1136/bmj.r2334 · Cited by 1
Antithrombotic therapy and thrombolysis: the present and the future
van der Hoek, S. A. (2014) · Utrecht University Repository (Utrecht University)
Conservative treatment of venous thromboembolism
Jirát, S., Marx, M. P., & Magage, S. (2015) · Reviews in vascular medicine · doi:10.1016/j.rvm.2015.06.002
Long-Term Management of Venous Thromboembolism: Strategies for Reducing the Risk of Recurrence
Piazza, G., Hohlfelder, B., & Goldhaber, S. Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-20843-5_10
Self-citationAisha, Q. (2014) · HEC National Digital Library
Aktuelle Therapie und Sekundärprävention der Lungenembolie
Lankeit, M., & Konstantinides, S. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0481-8
Response to Re: Thrombin inhibitors: surgical considerations and pharmacology
Breik, O., Tadros, R., & Devitt, P. G. (2013) · ANZ Journal of Surgery · doi:10.1111/ans.12323
Nieto-Rodríguez, J. A., & Cámara-González, T. (2015) · Revista Clínica Española · doi:10.1016/j.rce.2015.07.001
Chapitre 31 – Thérapeutique de la thrombose veineuse profonde
Élias, A., & Pernod, G. (2015) · doi:10.1016/b978-2-294-74489-1.00031-0
The evolving role of dabigatran etexilate in clinical practice
Hellenbart, E. L., Drambarean, B., Lee, J. C., & Nutescu, E. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1074179
“Drug name Dabigatran etexilate (marketed as Pradaxa , Pradax , Prazaxa ) Approved Indications VTE prevention following hip or knee replacement surgery (EU, Canada) Nonvalvular atrial fibrillation (USA, EU, Canada) Treatment of deep vein thrombosis and pulmonary embolism (USA, EU, Canada) Pharmacology Direct thrombin i…”
ResultInfluentialDouketis, J. D., Bell, A., Eikelboom, J. W., & Liew, A. (2014) · Europe PMC (PubMed Central)
Rivaroxaban pour le traitement de l’embolie pulmonaire symptomatique : Étude EINSTEIN-PE
Crevier, B., Jodoin-Poirier, M.-È., Yee, J., & Thiboutot, Z. (2014) · Pharmactuel
Dabigatran for longer term anticoagulation
Linden, B. (2013) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2013.8.4.168
Faure, S. (2013) · Actualités Pharmaceutiques · doi:10.1016/j.actpha.2013.02.014
Diagnostic et traitement de la maladie thromboembolique veineuse en 2013
Mavrakanas, T. A., & Perrier, A. (2014) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(14)71482-x
Adequate Management of Venous Thromboembolism
Hata, S. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0036
Role of the new oral anticoagulants in treatment of venous throboembolism
Minichiello, T., & Garcia, D. A. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0916-x
Thrombosis – Besieged but Poorly Understood
Lang, I. M. (2014) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2014.00004 · Cited by 1
“Dabigatran (38) Reduction of the risk of recurrence of DVT”
BackgroundÁcido acetilsalicílico en el tratamiento extendido de la enfermedad tromboembólica venosa
Riera‐Mestre, A., & Formiga, F. (2015) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2014.12.001
Kodani, E. (2013) · Journal of Cardiology Cases · doi:10.1016/j.jccase.2013.06.003
“[9] Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ.”
BackgroundRespiratory Review of 2014: Pulmonary Thromboembolism
Lee, J. S. (2014) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2014.77.3.105
Aktuelle Therapie und Sekundärprävention der Lungenembolie
Lankeit, M., & Konstantinides, S. (2013) · Der Pneumologe · doi:10.1007/s10405-013-0744-x
“Die Dauer der therapeutischen Anti koagulation ist abhängig zu ma chen vom individuellen Risikoprofil des Patienten Bei Patienten mit Krebserkrankung wird empfohlen, die therapeutische Antikoagulation für die Dauer der aktiven Erkrankung fortzuführen 450 | Der Pneumologe 6 · 2013 CME F In der RE-SONATE-Studie war Dabi…”
Influential¿Qué aportan los nuevos anticoagulantes en la prevención del tromboembolismo venoso y arterial?
Dalmau, F. G.-B. (2014) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2014.03.001 · Cited by 1
RENAL FUNCTION IN RELATION TO GENTAMICIN AND DABIGATRAN CLEARANCE AND DOSING
Ken, P., & Chin, L. (2014)
Use of ASA after warfarin for unprovoked VTE.
Allan, G. M., Banh, H. L., & Ference, J. D. (2013) · Europe PMC (PubMed Central)
Expanding horizons of anticoagulant therapy: Dabigatran etexilate a novel oral anticoagulant
Jadhav, P. R., Ray, I., Vieira, A., Ghanekar, J., & Deshmukh, Y. A. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20131031
The treatment of venous thromboembolism with new oral anticoagulants
Imberti, D. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2013.s8.29
Análise custo-efectividade dos novos anticoagulantes orais
Ferreira, J. P. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Landini, G., & Masotti, L. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2013.s8.41
Dabigatran for Extended Treatment of Venous Thromboembolism
Brett, A. S. (2013) · Journal watch · doi:10.1056/jw201302280000001
Will They Have an Impact? A Closer Look at Recent Nt th T i l Noteworthy Trials
Ellinger, L. K. (2013)
Ward, M., & Ranger, N. S. (2015)
Aktuelle Therapie und Sekundärprävention der Lungenembolie
Lankeit, M., & Konstantinides, S. (2014) · Gefässchirurgie · doi:10.1007/s00772-013-1286-6
Joseph, D. E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9560-4_16
Anticoagulantes orais: velho versus novo
Peres, D. S. L. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Damit das Blut nicht in den Adern stockt ... Neue orale Antikoagulanzien oder doch Macumar?
Pötzsch, B. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-2868-2
Edoxaban in the secondary prevention of VTE
Levy, J. H., & Hunt, B. J. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00037-5
Venös tromboembolism och medel mot trombos
Schulman, S. (2012)
Self-citationTratamiento del Tromboembolismo Venoso: que hay de nuevo
Schulman, S. (2015)
Self-citationPulmonary embolism: clinical guidelines of European Society of Cardiology (2014)*
Article, E. (2015) · PULMONOLOGIYA · doi:10.18093/0869-0189-2015-25-6-649-684
Es lohnt sich heute, länger zu antikoagulieren: Venöse Thromboembolie
Einecke, D. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-0486-z
Frade, G., & Javier, L. (2014) · University of Valladolid Documentary Repository (University of Valladolid)
Nieuwe orale anticoagulantia: Wanneer gebruiken in de huisartsenpraktijk?
Gyselaers, J., Gijsen, G., Gijsen, S. E., Smeets, M., Dewitte, H., & Vaes, B. (2015) · Huisarts Nu · doi:10.1007/s40954-015-0099-0 · Cited by 1
Anticoagulants oraux directs : quels facteurs de risque d'une concentration plasmatique élevée ?
Mutte, F.-A. (2016) · HAL · Cited by 1
Enrique, R., & Mata, L. A. C. (2014)
(2016) · Wiley eBooks · doi:10.1002/9781119039112.ch107
Thrombininhibitor so wirksam wie Vitamin-K-Antagonist: Verlängerte Thrombose-Behandlung
Diehm, C. (2013) · CardioVasc · doi:10.1007/s15027-013-0130-y
Anticoagulation Drugs: Indications, Therapeutic Monitoring, and Antidotes
Sharda, A. V., & Zwicker, J. I. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_44
Pettinari, I. (2016) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/7351
Roy, P. (2016) · European Respiratory Journal · doi:10.1183/13993003.01646-2016
Tratamiento periprocedimiento en pacientes con fibrilación auricular que reciben anticoagulantes
Astudillo-Ramírez, B. V. (2016) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.10.011
Update on Direct Oral Anticoagulants and Their Uses
Bang, V. V., Zide, R. S., & Huang, C.-C. (2017) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2016.11.004
Post thrombotic syndrome, exploring aspects of pathophysiology and personalized management
Bouman, A. C. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20160218ab
Pulmoner Embolinin Güncel Tedavisi
Tekin, A. (2016) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.248425
Approche à l’égard des nouveaux anticoagulants oraux en pratique familiale
Douketis, J. D., Bell, A., Eikelboom, J. W., & Liew, A. (2014) · Canadian Family Physician · Cited by 1
ディベート1 : 静脈血栓塞栓症予防 : アスピリンは是か非か あくまでピンチヒッターでしかないアスピリン
悟, 藤. (2015) · 心臓 · doi:10.11281/shinzo.47.882
García, M., & del Rocío, A. (2016) · Repositorio Institucional de la Universidad de Málaga (University of Málaga)
Dürschmied, D., Heinz, J., Siepe, M., & Bode, C. (2015)
Lindhoff‐Last, E., & Haberichter, B. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0200-y
Long-term strategies in patients with unprovoked venous thromboembolism
Prandoni, P. (2017) · Phlebologie · doi:10.12687/phleb2372-5-2017
Ryzhkin, V., Vorontsova, A. V., Lobastov, K. V., Schastlivtsev, I., Barinov, V., Naumov, E. K., & Laberko, L. A. (2017) · Journal of Venous Disorders · doi:10.17116/flebo2017113131-141
Risque hémoragique sous anticoagulants : Vers une prise en charge personnalisée
Moustafa, F. (2017) · theses.fr (ABES) · doi:10.70675/4305dae7zb706z4356z9c18z3503fb20b482
Mój pacjent leczony sulodeksydem — kiedy i dlaczego stosuję?
Gorczyca−Michta, I., & Wożakowska−Kapłon, B. (2017) · Folia Cardiologica · doi:10.5603/fc.2017.0109 · Cited by 1
Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases
Tomić, M., Novakovic, A., Milojević, P. S., Nenezić, D., Stojanovic, I. C., & Gajin, P. (2017) · Medicinski casopis · doi:10.5937/mckg51-15563
Stoberock, K., Larena-Avellaneda, A. A., Kölbel, T., Atlihan, G., Rohlffs, F., Behrendt, C., & Debus, E. S. (2018) · Gefässchirurgie · doi:10.1007/s00772-018-0362-3
Extrahepatic Portal Vein Obstruction: Asian and Global Perspective
Maiwall, R., & Sarin, S. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-72628-1_18
“Systemic anticoagulation is therefore only indicated in the presence of an underlying prothrombotic state [110, 111].”
BackgroundThrombose, Lungenembolie und Antikoagulation: Wie und wie lange antikoagulieren?
Geisler, T., & Stimpfle, F. (2018) · Der Klinikarzt · doi:10.1055/a-0575-1650
“N Engl J Med 2012; 367: 1979–1987 [23] Schulman S, Kearon C, Kakkar AK et al.”
BackgroundAnticoagulation in Venous Thromboembolism
Barnes, G. D., & Renner, E. T. (2018) · Springer eBooks · doi:10.1007/978-3-319-73709-6_14
Quelle durée de traitement après un événement thromboembolique veineux ?
Couturaud, F., & Mahé, I. (2018) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.03.383
Mitic, G. P. (2014) · Srce i krvni sudovi · doi:10.5937/siks1403188m
Vanassche, T., & de Werf, F. V. (2018) · THE BANGKOK MEDICAL JOURNAL · doi:10.31524/bkkmedj.2018.09.015
Sulodeksyd w zapobieganiu nawrotom zakrzepicy żył głębokich – badanie SURVET
Madycki, G. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0013
Cho, J. H., & Kim, Y. (2018) · Clinical & Experimental Thrombosis and Hemostasis · doi:10.14345/ceth.18001
Association between dabigatran etexilate and risk of myocardial infarction
Zhao, H., & Chen, X. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.015
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.